Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Morocco Pharmaceuticals And Healthcare
Industry SWOT — 6
Pharmaceutical Business Environment
Ratings — 7
Table: Regional Business Environment
Ratings — 7
Risks To Realisation Of
Returns — 8
Market Summary — 10
Table:
Morocco’s Drug Market By Segment, 2003-2013 — 11
Regulatory Regime — 12
Intellectual
Property — 12
Pricing and Reimbursement
Regime — 12
Industry Developments — 14
Epidemiology — 14
Table: Leading Causes Of Death In
Morocco, 2002 — 15
Healthcare
Sector — 16
Healthcare Reforms — 18
Health Insurance — 19
Pharmaceutical
Sector — 20
Pharmaceutical
Distribution — 23
Research &
Development — 23
Industry Forecast
Scenario — 25
Overall Market
Forecasts — 25
Table: Morocco’s Drug Market
Expenditure, 2003-2013 — 26
Key Growth Factors –
Industry — 27
Table: Morocco’s Health Expenditure,
2003-2013 — 28
Economic Activity — 29
Table: Morocco - Economic Activity, 2006 – 2013 — 31
Prescription Drug Market Forecast — 32
Table:
Morocco’s Prescription Drug Market, 2003-2013 (US$mn unless otherwise
stated) — 33
Patented Drug Market
Forecast — 34
Table: Morocco’s Patented Drug Market,
2003-2013 — 34
Generic Drug Market
Forecast — 35
Table: Morocco’s Generic Drug Market,
2003-2013 — 36
OTC Drug Market
Forecast — 37
Table: Morocco’s OTC Drug Market
2003-2013 (US$mn unless otherwise stated) — 38
Medical
Device Market Forecast — 39
Table: Morocco’s
Pharmaceutical Device Forecast, 2003-2013 — 41
Pharmaceutical Export/Import Forecasts — 42
Table:
Morocco’s Pharmaceutical Trade Balance, 2004-2013
(US$mn) — 43
Other Healthcare Data
Forecasts — 44
Table: Morocco’s Other Health
Indicators, 2003-2013 — 44
Key Risks To BMI’s
Forecasts — 44
Competitive
Landscape — 45
Company Profiles — 46
Sanofi-Aventis — 46
Pfizer — 48
GlaxoSmithKline — 49
Indigenous
Producers — 50
Sothema — 50
Laprophan — 52
Promopharm — 54
Country
Snapshot: Morocco Demographic Data — 55
Section 1:
Population — 55
Table: Demographic Indicators,
2005-2030 — 55
Table: Rural/Urban Breakdown,
2005-2030 — 56
Section 2: Education and
Healthcare — 56
Table: Education,
2002-2005 — 56
Table: Vital Statistics,
2005-2030 — 56
Section 3: Labour Market and Spending
Power — 57
Table: Employment Indicators,
2001-2006 — 57
Table: Consumer Expenditure, 2000-2012
(US$) — 57
BMI Forecast Modelling — 58
Ratings Overview — 59
Table: Pharmaceutical Business
Environment Indicators — 60
Weighting — 61
Table: Weighting Of
Components — 61
| 
View Cart
